🚨: The @FDA has granted accelerated approval to the immunotherapy Jemperli (dostarlimab) for adults with stage 2 or 3 rectal cancer whose tumors have specific genetic characteristics known as mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H). The approach, developed at MSK by gastrointestinal medical oncologists Dr. Andrea Cercek (@AndreaCercek) and Dr. Luis Diaz Jr. (@ldiaz1971), uses immunotherapy alone to harness the body’s own immune system to fight cancer. This allows some patients to skip standard treatment for rectal cancer, which includes surgery, radiation, and chemotherapy, and can have life-altering consequences for bowel and urinary function, as well as fertility. Learn more: bit.ly/4zEQoil

Specialists at MSK know how to modify tests and treatment protocols to navigate the special needs of people who have cancer during pregnancy. Beyond the medical expertise, MSK also offers emotional support for expectant mothers facing a heartbreaking circumstance. “We are seeing this situation more often because of the rise in certain cancers among younger people,” says MSK psychologist Dr. Amanda Balakirsky. “Being pregnant with cancer can cause a lot of grief and feelings of isolation. We try to normalize the experience as best we can, to help them adjust from what they were expecting in their pregnancy and feeling different from their peers.” Learn more about how they helped one patient and her now 1.5-year-old son: bit.ly/4engGNV

We're proud to share that Dr. Ross Levine, Chief Scientific Officer at MSK and Dr. @dana_peer, Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) at MSK, have been elected to the @theNAMedicine. With these latest appointments, 30 MSK faculty members have now received this prestigious honor. Learn more about these two elections: bit.ly/3VWdHWq

Researchers at MSK and their collaborators are gaining new insights into cancer cachexia, a wasting syndrome that affects nearly half of all patients. Findings in @NatureMedicine could help predict which patients are most at risk and help facilitate timely support and interventions. Learn more: bit.ly/4yhYfl3

#Lungcancer, both small cell lung cancer (#SCLC) and non-small cell lung cancer (#NSCLC), is the second-most common cancer in the United States. "Lung adenocarcinoma, a type of NSCLC, is the most common type of lung cancer, and when caught at an early stage, it can be highly treatable. And for patients with stage one disease, surgery can often be curative," says Dr. David Jones (@JonesDavid2013), MSK's Chief of Thoracic Surgery. "If the cancer has spread to nearby lymph nodes, additional treatment may be recommended to reduce the risk of recurrence." Learn more about advances in lung cancer treatments and the advantages of coming to MSK when you are first diagnosed: bit.ly/3VLzf8b

DYK: The most common signs and symptoms of lung cancer are the same in men and women? To name a few: 🔹 A persistent cough, including coughing up blood 🔹 Wheezing or shortness of breath 🔹 Chest pain 🔹 Hoarseness 🔹 Unexplained weight loss MSK thoracic oncologist Dr. Helena Yu also shares why lung cancer is more common in women than men in younger age groups and why people get lung cancer even if they’ve never smoked: bit.ly/4BjXKts

A new MSK study co-authored by MSK's @StadlerZsofia and Dr. Luis Diaz Jr., published in @CC_AACR, found that limiting genetic testing to patients under 50 would have missed 72% of those with inherited cancer mutations. Knowing about these mutations can help guide treatment and help family members understand their cancer risk. Learn more: bit.ly/4jTtgbf

Congrats to MSK's most recent awards and appointments, including @StadlerZsofia for being appointed Chief of MSK’s Clinical Genetics Service, @seungjaylee for being named a finalist for the 2026 @BlavatnikAwards for Young Scientists, Dr. Abigail Xie for receiving the 2026 @IMPvienna International Birnstiel Award, and more: bit.ly/4du0iuB

Congratulations to gastrointestinal medical oncologist and clinical geneticist Dr. Zsofia Stadler (@StadlerZsofia), who has been appointed Chief of the Clinical Genetics Service at MSK. Dr. Stadler has served as Clinical Director of the Clinical Genetics Service since 2017, helping expand genetics-driven cancer care, clinical operations, and translational research at MSK. Her work has advanced the understanding and clinical application of inherited cancer risk, including research in Lynch syndrome, germline genetic testing, cancer prevention, and precision oncology. Join us in welcoming Dr. Stadler to her new role by commenting below. 👏

🎉 Congratulations to MSK radiation oncologists Dr. Christopher Barker, Dr. Daphna Gelblum, and Dr. Abraham Wu on being named 2026 ASTRO Fellows, recognizing their contributions to radiation oncology! @MSK_RadOnc #ASTRO2026

Lobular breast cancer is the second most common type of breast cancer, but it can be harder to detect on mammograms and during breast exams. MSK experts @SherryShenMD, @FresiaPareja, and Dr. Anita Mamtani explain its symptoms, diagnosis, and treatment. Learn more: bit.ly/3VuHBkr

The @FDA recently approved a targeted therapy called lirafugratinib (Lyrfigtu) for people with advanced cholangiocarcinoma (bile duct cancer) that has a genetic change called an FGFR2 fusion or an FGFR2 rearrangement. The clinical trial that resulted in the drug’s approval was led by MSK early drug development specialist Dr. @AliSchram. “Cholangiocarcinoma is a rare cancer that is almost always caught after it has spread, making it extremely challenging to treat,” Dr. Schram says. “Any time we find a new treatment for patients with this disease, it can make a meaningful difference to them and their families.” Learn more about this approval: bit.ly/4hZw319

A new study from MSK and collaborators (@jonasschluter and @DrMvandenBrink) suggests that consuming high levels of sugar while taking antibiotics may worsen gastrointestinal side effects in patients receiving bone marrow transplants. The study, co-led by Dr. Jonathan “Tsoni” Peled (@tsonipeled) and published in @Nature, tracked the diets and gut microbiomes of 173 hospitalized transplant patients. The data showed that high-sugar foods and antibiotics appeared to compound damage to the microbiome. Learn more about what these findings could mean for nutrition during cancer treatment: bit.ly/4AH2wRc